Rituximab in refractory autoimmune bullous diseases. (Q36484979)

From Wikidata

Jump to navigation Jump to search

scientific article

edit

Language	Label	Description	Also known as
English	Rituximab in refractory autoimmune bullous diseases.	scientific article

Statements

instance of

scholarly article

1 reference

stated in

Europe PubMed Central

PubMed publication ID

16716150

reference URL

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16716150%20AND%20SRC:MED&resulttype=core&format=json

retrieved

28 January 2020

review article

1 reference

stated in

Europe PubMed Central

title

Rituximab in refractory autoimmune bullous diseases (English)

1 reference

stated in

Europe PubMed Central

PubMed publication ID

16716150

reference URL

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16716150%20AND%20SRC:MED&resulttype=core&format=json

retrieved

28 January 2020

main subject

rituximab

1 reference

based on heuristic

inferred from title

author

Enno Schmidt

series ordinal

1

1 reference

stated in

Europe PubMed Central

PubMed publication ID

16716150

reference URL

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16716150%20AND%20SRC:MED&resulttype=core&format=json

retrieved

28 January 2020

author name string

Hunzelmann N

series ordinal

2

1 reference

stated in

Europe PubMed Central

PubMed publication ID

16716150

reference URL

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16716150%20AND%20SRC:MED&resulttype=core&format=json

retrieved

28 January 2020

Zillikens D

series ordinal

3

1 reference

stated in

Europe PubMed Central

PubMed publication ID

16716150

reference URL

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16716150%20AND%20SRC:MED&resulttype=core&format=json

retrieved

28 January 2020

Bröcker EB

series ordinal

4

1 reference

stated in

Europe PubMed Central

PubMed publication ID

16716150

reference URL

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16716150%20AND%20SRC:MED&resulttype=core&format=json

retrieved

28 January 2020

Goebeler M

series ordinal

5

1 reference

stated in

Europe PubMed Central

PubMed publication ID

16716150

reference URL

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16716150%20AND%20SRC:MED&resulttype=core&format=json

retrieved

28 January 2020

publication date

1 July 2006

1 reference

stated in

Europe PubMed Central

PubMed publication ID

16716150

reference URL

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16716150%20AND%20SRC:MED&resulttype=core&format=json

retrieved

28 January 2020

published in

Clinical and Experimental Dermatology

1 reference

stated in

Europe PubMed Central

PubMed publication ID

16716150

reference URL

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16716150%20AND%20SRC:MED&resulttype=core&format=json

retrieved

28 January 2020

volume

31

1 reference

stated in

Europe PubMed Central

PubMed publication ID

16716150

reference URL

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16716150%20AND%20SRC:MED&resulttype=core&format=json

retrieved

28 January 2020

issue

4

1 reference

stated in

Europe PubMed Central

PubMed publication ID

16716150

reference URL

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16716150%20AND%20SRC:MED&resulttype=core&format=json

retrieved

28 January 2020

page(s)

503-508

1 reference

stated in

Europe PubMed Central

PubMed publication ID

16716150

reference URL

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16716150%20AND%20SRC:MED&resulttype=core&format=json

retrieved

28 January 2020

cites work

Rituximab in autoimmune diseases

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1111%2FJ.1365-2230.2006.02151.X

retrieved

21 January 2018

Mice carrying a CD20 gene disruption

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1111%2FJ.1365-2230.2006.02151.X

retrieved

21 January 2018

Cellular and molecular signal transduction pathways modulated by rituximab (rituxan, anti-CD20 mAb) in non-Hodgkin's lymphoma: implications in chemosensitization and therapeutic intervention

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1111%2FJ.1365-2230.2006.02151.X

retrieved

21 January 2018

Treatment of childhood autoimmune haemolytic anaemia with rituximab

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1111%2FJ.1365-2230.2006.02151.X

retrieved

21 January 2018

Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1111%2FJ.1365-2230.2006.02151.X

retrieved

21 January 2018

The relationship of FcgammaRIIIa genotype to degree of B cell depletion by rituximab in the treatment of systemic lupus erythematosus.

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1111%2FJ.1365-2230.2006.02151.X

retrieved

21 January 2018

T-cellular autoimmunity against desmogleins in pemphigus, an autoantibody-mediated bullous disorder of the skin

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1111%2FJ.1365-2230.2006.02151.X

retrieved

21 January 2018

Successful treatment of paraneoplastic pemphigus in follicular NHL with rituximab: report of a case and review of treatment for paraneoplastic pemphigus in NHL and CLL.

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1111%2FJ.1365-2230.2006.02151.X

retrieved

21 January 2018

Follicular non-Hodgkin's lymphoma with refractory paraneoplastic pemphigus: case report with review of novel treatment modalities

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1111%2FJ.1365-2230.2006.02151.X

retrieved

21 January 2018

Treatment of refractory pemphigus vulgaris with rituximab (anti-CD20 monoclonal antibody).

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1111%2FJ.1365-2230.2006.02151.X

retrieved

21 January 2018

Successful treatment of refractory childhood pemphgus vulgaris with anti-CD20 monoclonal antibody (rituximab).

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1111%2FJ.1365-2230.2006.02151.X

retrieved

21 January 2018

Treatment of resistant pemphigus vulgaris with an anti-CD20 monoclonal antibody (Rituximab).

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1111%2FJ.1365-2230.2006.02151.X

retrieved

21 January 2018

Long-term complete remission of severe pemphigus vulgaris with monoclonal anti-CD20 antibody therapy and immunophenotype correlations.

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1111%2FJ.1365-2230.2006.02151.X

retrieved

21 January 2018

B cell depletion as a novel treatment for systemic lupus erythematosus: a phase I/II dose-escalation trial of rituximab

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1111%2FJ.1365-2230.2006.02151.X

retrieved

21 January 2018

Combination treatment of bullous pemphigoid with anti-CD20 and anti-CD25 antibodies in a patient with chronic graft-versus-host disease

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1111%2FJ.1365-2230.2006.02151.X

retrieved

21 January 2018

Successful adjuvant treatment of recalcitrant epidermolysis bullosa acquisita with anti-CD20 antibody rituximab

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1111%2FJ.1365-2230.2006.02151.X

retrieved

21 January 2018

Therapy of refractory pemphigus vulgaris with monoclonal anti-CD20 antibody (rituximab)

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1111%2FJ.1365-2230.2006.02151.X

retrieved

21 January 2018

Anti-CD20 monoclonal antibody (rituximab) in the treatment of pemphigus

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1111%2FJ.1365-2230.2006.02151.X

retrieved

21 January 2018

Rapid response of treatment-resistant pemphigus foliaceus to the anti-CD20 antibody rituximab

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1111%2FJ.1365-2230.2006.02151.X

retrieved

21 January 2018

Long-standing remission of recalcitrant juvenile pemphigus vulgaris after adjuvant therapy with rituximab

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1111%2FJ.1365-2230.2006.02151.X

retrieved

21 January 2018

Anti-CD20 chimeric monoclonal antibody (rituximab) for the treatment of recalcitrant, life-threatening pemphigus vulgaris with implications in the pathogenesis of the disorder

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1111%2FJ.1365-2230.2006.02151.X

retrieved

21 January 2018

Identifiers

DOI

10.1111/J.1365-2230.2006.02151.X

1 reference

stated in

Europe PubMed Central

PubMed publication ID

16716150

reference URL

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16716150%20AND%20SRC:MED&resulttype=core&format=json

retrieved

28 January 2020

PubMed publication ID

16716150

1 reference

stated in

Europe PubMed Central

PubMed publication ID

16716150

reference URL

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16716150%20AND%20SRC:MED&resulttype=core&format=json

retrieved

28 January 2020

ResearchGate publication ID

7065918

0 references

 

Sitelinks

Wikipedia(0 entries)

edit

Wikibooks(0 entries)

edit

Wikinews(0 entries)

edit

Wikiquote(0 entries)

edit

Wikisource(0 entries)

edit

Wikiversity(0 entries)

edit

Wikivoyage(0 entries)

edit

Wiktionary(0 entries)

edit

Multilingual sites(0 entries)

edit

Retrieved from "https://www.wikidata.org/w/index.php?title=Q36484979&oldid=1561123991"